Monitoring veterans for metabolic side effects when prescribing antipsychotics

Psychiatric Services

Volumn 64, Issue 1, 2013, Pages 28-35

  Mittal, Dinesh ^a,b   Li, Chenghui ^a,c   Williams, James Silas ^a   Viverito, Kristen ^a,b   Landes, Reid D ^a,b   Owen, Richard R ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; BODY WEIGHT; CLINICAL PRACTICE; COHORT ANALYSIS; CONSENSUS; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG MONITORING; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEALTH CARE FACILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METABOLIC PARAMETERS; OUTPATIENT; PRESCRIPTION; PSYCHIATRIC DIAGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SCHIZOPHRENIA; VETERAN; BLOOD; CONFIDENCE INTERVAL; DRUG EFFECT; FACTUAL DATABASE; GLUCOSE BLOOD LEVEL; MIDDLE AGED; PSYCHOLOGICAL ASPECT; RISK; UNITED STATES;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; BODY WEIGHT; CHOLESTEROL, LDL; CONFIDENCE INTERVALS; DATABASES, FACTUAL; DRUG MONITORING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; RETROSPECTIVE STUDIES; UNITED STATES; VETERANS;

MLCS; MLOWN;

EID: 84878871368     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.201100445     Document Type: Article

References (35)

1. Leslie DL, Mohamed S, Rosenheck RA: Off-label use of antipsychotic medications in the Department of Veterans Affairs health care system. Psychiatric Services 60: 1175-1181, 2009
2. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists, et al: Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 27:596-601, 2004
3. Newcomer JW, Hennekens CH: Severe mental illness and risk of cardiovascular disease. JAMA 298:1794-1796, 2007
4. Marder SR, Essock SM, Miller AL, et al: Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry 161:1334-1349, 2004
5. van Winkel R, De Hert M, Wampers M, et al: Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry 69: 472-479, 2008
6. Rummel-Kluge C, Komossa K, Schwarz S, et al: Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophrenia Research 123:225-233, 2010
7. Morrato EH, Druss B, Hartung DM, et al: Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for secondgeneration antipsychotic drugs. Archives of General Psychiatry 67:17-24, 2010
8. Morrato EH, Nicol GE, Maahs D, et al: Metabolic screening in children receiving antipsychotic drug treatment. Archives of Pediatrics and Adolescent Medicine 164: 344-351, 2010
9. Morrato EH, Druss BG, HartungDM, et al: Small area variation and geographic and patient-specific determinants of metabolic testing in antipsychotic users. Pharmacoepidemiology and Drug Safety 20:66-75, 2011
10. Morrato EH, Newcomer JW, Allen RR, et al: Prevalence of baseline serum glucose and lipid testing in users of secondgeneration antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. Journal of Clinical Psychiatry 69: 316-322, 2008
11. Hsu C, Ried LD, Bengtson MA, et al: Metabolic monitoring in veterans with schizophrenia-related disorders and treated with second-generation antipsychotics: findings from a Veterans Affairs-based population. Journal of the American Pharmacists Association 48:393-400, 2008
12. Haupt DW, Rosenblatt LC, Kim E, et al: Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. American Journal of Psychiatry 166:345-353, 2009
13. Morrato EH, Cuffel B, Newcomer JW, et al: Metabolic risk status and secondgeneration antipsychotic drug selection: a retrospective study of commercially insured patients. Journal of Clinical Psychopharmacology 29:26-32, 2009
14. Morrato EH, Newcomer JW, Kamat S, et al: Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes Care 32:1037-1042, 2009
15. Mitchell AJ, Delaffon V, Vancampfort D, et al: Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychological Medicine 42:125-147, 2012
16. Weissman EM, Zhu CW, Schooler NR, et al: Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics. Journal of Clinical Psychiatry 67:1323-1326, 2006
17. Khatana SA, Kane J, Taveira TH, et al: Monitoring and prevalence rates of metabolic syndrome in military veterans with serious mental illness. PLoS ONE 6:e19298, 2011
18. Shi L, Ascher-Svanum H, Chiang YJ, et al: Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration. BMC Psychiatry 9:80, 2009
19. Lee TA, Shields AE, Vogeli C, et al: Mortality rate in veterans with multiple chronic conditions. Journal of General Internal Medicine 22(suppl 3):403-407, 2007
20. Perry TW, Pugh MJ, Waterer GW, et al: Incidence of cardiovascular events after hospital admission for pneumonia. American Journal of Medicine 124:244-251, 2011
21. Blow FC, McCarthy JF, Valenstein M, et al: Care for Veterans with Psychosis in the Veterans Health Administration, FY06 8th Annual National Psychosis Registry. Ann Arbor, Mich, Serious Mental Illness Treatment Research and Evaluation Center, Health Services Research and Development Center of Excellence, 2007
22. Allison DB, Mentore JL, Heo M, et al: Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 156:1686-1696, 1999
23. Nussbaum AM, Stroup TS: Paliperidone for treatment of schizophrenia. Schizophrenia Bulletin 34:419-422, 2008
24. Lieberman JA, Stroup TS, McEvoy JP, et al; Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353: 1209-1223, 2005
25. Kilbourne AM, Post EP, Bauer MS, et al: Therapeutic drug and cardiovascular disease risk monitoring in patients with bipolar disorder. Journal of Affective Disorders 102: 145-151, 2007
26. Jennex A, Gardner DM: Monitoring and management of metabolic risk factors in outpatients taking antipsychotic drugs: a controlled study. Canadian Journal of Psychiatry 53:34-42, 2008
27. Copeland LA, Parchman ML, Zeber JE, et al: Prediabetes assessment and follow-up in older veterans with schizophrenia. American Journal of Geriatric Psychiatry 18: 887-896, 2010
28. Suppes T, McElroy SL, Hirschfeld R: Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder: a survey of 500 US psychiatrists. Psychopharmacology Bulletin 40:22-40, 2007
29. Bauer M, Lecrubier Y, Suppes T: Awareness of metabolic concerns in patients with bipolar disorder: a survey of European psychiatrists. European Psychiatry 23: 169-177, 2008
30. Bowers L, Ross J, Owiti J, et al: Event sequencing of forced intramuscular medication in England. Journal of Psychiatric and Mental Health Nursing 19:799-806, 2012
31. Correll CU, Druss BG, Lombardo I, et al: Findings of a US national cardiometabolic screening program among 10,084 psychiatric outpatients. Psychiatric Services 61: 892-898, 2010
32. Women's Health, USA 2010. Rockville, Md, US Department of Health and Human Services, 2010
33. Long JA, Bamba MI, Ling B, et al: Missing race/ethnicity data in Veterans Health Administration based disparities research: a systematic review. Journal of Health Care for the Poor and Underserved 17:128-140, 2006
34. McKnight W: Metabolic syndrome risk in patients prescribed atypical antipsychotics: as comorbidities multiply, the debate over monitoring responsibilities continues. Psychiatric Annals 41:347-349, 2011
35. Smith JL, Owen RR, Curran GM: Barriers to Following Guideline Recommendations for Antipsychotic Medication Management. Presented at the AcademyHealth Annual Research Meeting, Seattle, Wash, June 25-27, 2006